Overview

Title: Does the UK’s Life Sciences Industrial Strategy and Sector Deal Make Brexit Easier to Swallow?

Date: Tuesday, May 22, 2018

Time: 12:00 PM British Summer Time

Duration: 1 hour


Register Now:

Summary

The UK is one of the leading countries for NCE (New Chemical Entity) launches, behind only the US and Germany, but will it lose its position because of Brexit?

IQVIA and Informa Pharma Intelligence recently conducted an industry-wide survey of over 120 life sciences professionals to gauge the potential impact of events on UK life sciences industry in the near to mid-term. As uncertainty reigns and the March 2019 exit deadline closes in, this in-depth survey revealed that the industry sees Brexit as having a net negative impact on the UK’s position as a priority launch country and clinical trial site. But will the UK’s Life Sciences Industrial Strategy and Sector Deal provide a lifeline for the industry? In this webinar hosted by Mike Ward, Chief Content Officer, Informa Pharma Intelligence Insights, the panel will examine the key findings of the survey and share their strategic insights on the attractiveness of the UK market to the global pharmaceutical industry.

Join this webinar to discover:

  • Key findings from the Attractiveness of the UK market to global pharmaceutical industry survey
  • The potential impact of Brexit on launches and clinical investment in the UK
  • How companies are navigating the uncertainty created by Brexit
  • Implementation of the UK’s Life Sciences Industrial Strategy and Sector Deal

Hosted by:

Mike Ward, Global Director of Content, Informa Pharma Insights

Speakers:

Angela McFarlane, Market Development Director, IQVIA

Mike Thompson, Chief Executive, The Association of the British Pharmaceutical Industry (ABPI)

Louise Houson, Managing Director for MSD in the UK and Ireland